Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E27.37 EPS (ttm)2.77 Insider Own0.10% Shs Outstand2.53B Perf Week4.56%
Market Cap191.35B Forward P/E11.35 EPS next Y6.67 Insider Trans-0.76% Shs Float2.53B Perf Month1.40%
Income7.03B PEG2.96 EPS next Q1.50 Inst Own75.20% Short Float0.78% Perf Quarter3.36%
Sales48.02B P/S3.98 EPS this Y-28.00% Inst Trans-0.68% Short Ratio1.53 Perf Half Y-4.30%
Book/sh10.65 P/B7.11 EPS next Y9.22% ROA7.70% Target Price93.29 Perf Year7.25%
Cash/sh- P/C- EPS next 5Y9.23% ROE25.80% 52W Range68.38 - 83.72 Perf YTD-2.95%
Dividend2.60 P/FCF976.28 EPS past 5Y12.20% ROI10.80% 52W High-7.85% Beta0.41
Dividend %3.43% Quick Ratio0.80 Sales past 5Y4.00% Gross Margin67.70% 52W Low12.82% ATR1.26
Employees74000 Current Ratio1.00 Sales Q/Q0.20% Oper. Margin14.60% RSI (14)63.06 Volatility1.69% 1.53%
OptionableYes Debt/Eq1.16 EPS Q/Q-1.00% Profit Margin14.60% Rel Volume1.09 Prev Close75.70
ShortableYes LT Debt/Eq0.89 EarningsApr 29 BMO Payout90.70% Avg Volume12.90M Price77.15
Recom2.10 SMA203.88% SMA504.47% SMA2002.36% Volume8,830,623 Change1.92%
May-20-21Downgrade Argus Buy → Hold
Apr-07-21Resumed RBC Capital Mkts Sector Perform $79
Nov-10-20Resumed Bernstein Outperform $95
Sep-29-20Initiated Berenberg Hold $88
Aug-03-20Upgrade Goldman Neutral → Buy $91 → $105
Jun-12-20Downgrade Wolfe Research Outperform → Peer Perform
Feb-27-20Initiated Barclays Overweight $93
Jan-07-20Initiated RBC Capital Mkts Sector Perform $99
Oct-17-19Resumed BofA/Merrill Neutral $90
Aug-16-19Initiated SVB Leerink Outperform
Jul-03-19Initiated Mizuho Buy $97
May-28-19Initiated Goldman Neutral
May-13-19Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Jun-16-21 10:33AM  
09:57AM  
08:00AM  
Jun-15-21 05:45PM  
03:20PM  
Jun-14-21 02:57PM  
01:47PM  
Jun-11-21 08:41AM  
Jun-10-21 10:05AM  
Jun-09-21 02:50PM  
12:58PM  
12:36PM  
12:34PM  
10:16AM  
08:47AM  
08:33AM  
07:17AM  
07:01AM  
06:45AM  
06:11AM  
Jun-08-21 02:03PM  
Jun-07-21 05:45PM  
04:30PM  
01:45PM  
09:47AM  
06:45AM  
Jun-04-21 02:50PM  
02:12PM  
10:31AM  
07:24AM  
07:20AM  
Jun-03-21 05:00PM  
05:00PM  
01:36PM  
12:42PM  
06:45AM  
05:52AM  
Jun-02-21 02:15PM  
01:44AM  
Jun-01-21 02:57PM  
01:00PM  
06:45AM  
06:45AM  
May-31-21 11:45AM  
May-28-21 01:43PM  
08:48AM  
May-27-21 05:47PM  
02:10PM  
10:12AM  
10:02AM  
May-26-21 02:52PM  
02:05PM  
02:03PM  
10:23AM  
08:00AM  
May-25-21 06:37PM  
03:40PM  
03:13PM  
02:44PM  
02:04PM  
09:17AM  
May-24-21 02:28PM  
01:51PM  
12:45PM  
10:28AM  
07:50AM  
06:49AM  
06:45AM  
May-23-21 06:01AM  
May-22-21 06:47AM  
May-21-21 03:14PM  
01:43PM  
10:01AM  
07:52AM  
07:36AM  
05:57AM  
May-20-21 01:58PM  
09:24AM  
06:45AM  
05:47AM  
May-19-21 01:49PM  
May-15-21 06:36AM  
May-14-21 03:29PM  
01:40PM  
11:45AM  
06:03AM  
May-13-21 02:27PM  
02:16PM  
06:45AM  
May-12-21 03:21PM  
02:14PM  
04:00AM  
May-11-21 02:09PM  
May-10-21 04:44PM  
01:53PM  
06:44AM  
May-07-21 05:45PM  
02:54PM  
02:04PM  
01:54PM  
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has an agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; and a collaboration agreement with Amathus Therapeutics to develop treatments for neurodegenerative diseases. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Clyburn FrankEVP & Pres ? Human HealthMay 10Option Exercise0.0019,3240113,672May 11 02:41 PM
Clyburn FrankEVP & Pres ? Human HealthMay 10Sale78.3219,3241,513,44094,348May 11 02:41 PM
Williams David MichaelEVP,Chief Info&Digital OfficerMay 04Option Exercise75.9841731,6845,662May 06 05:04 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise75.981,21292,08836,215May 06 05:02 PM
Litchfield CarolineEVP & CFOMay 04Option Exercise75.981,03978,94320,230May 06 05:01 PM
LeCointe-Cephas LisaSVP Chief Ethics & Com OfficerMay 04Option Exercise75.9869452,7302,612May 06 04:48 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 04Option Exercise75.981,906144,81895,287May 06 04:40 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 03Option Exercise74.5087565,18835,303May 04 04:50 PM
Williams David MichaelEVP,Chief Info&Digital OfficerMay 03Option Exercise74.5041230,6945,387May 04 04:55 PM
LeCointe-Cephas LisaSVP Chief Ethics & Com OfficerMay 03Option Exercise74.5043732,5562,068May 04 05:04 PM
Li Dean YExecutive VP & President, MRLMay 03Option Exercise74.5075055,87512,111May 04 04:57 PM
Litchfield CarolineEVP & CFOMay 03Option Exercise74.5075055,87519,544May 04 05:01 PM
Litchfield CarolineEVP & CFOMay 01Option Exercise74.5084062,58019,082May 04 05:01 PM
Li Dean YExecutive VP & President, MRLMay 01Option Exercise74.501,03076,73511,715May 04 04:57 PM
LeCointe-Cephas LisaSVP Chief Ethics & Com OfficerMay 01Option Exercise74.5062246,3391,841May 04 05:04 PM
Williams David MichaelEVP,Chief Info&Digital OfficerMay 01Option Exercise74.5056041,7205,167May 04 04:55 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 01Option Exercise74.5090167,12434,737May 04 04:50 PM
FRAZIER KENNETH CChairman, President & CEONov 09Sale81.42280,00022,797,011411,546Nov 12 04:45 PM
Nally MichaelEVP, Chief Marketing OfficerOct 30Option Exercise75.892,287173,56013,403Nov 03 04:48 PM
MIZELL STEVENEVP, Chief HR OfficerOct 30Option Exercise75.894,574347,1217,624Nov 03 04:44 PM
Clyburn FrankEVP, Chief Commercial OfficerOct 30Option Exercise75.892,287173,56083,656Nov 03 04:55 PM
Davis Robert MEVP, Global Svcs & CFOOct 05Option Exercise0.00251,2730422,329Oct 06 04:52 PM
Davis Robert MEVP, Global Svcs & CFOOct 05Sale81.03251,27320,360,325171,056Oct 06 04:52 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 13Sale83.0110,380861,67667,373Aug 17 06:36 PM
Clyburn FrankEVP, Chief Commercial OfficerAug 05Option Exercise0.0018,876099,639Aug 06 04:53 PM
Clyburn FrankEVP, Chief Commercial OfficerAug 05Sale81.5518,8761,539,27480,763Aug 06 04:53 PM
Gerberding Julie L.EVP Strat Comm, GI Pub PolicyJul 17Option Exercise0.0018,111062,862Jul 20 04:53 PM
Gerberding Julie L.EVP Strat Comm, GI Pub PolicyJul 17Sale80.0036,2852,902,97626,577Jul 20 04:53 PM